World AMR Awareness Week 2025: Working with Researchers to Stop Antimicrobial Resistance

In 2025, AMR action goes beyond raising awareness. It is also about showcasing tangible progress across research, innovation and collaboration. Within the AMR Accelerator, we put the spotlight on people contributing to the fight against AMR. Together, AMR Accelerator researchers at all stages are showing how coordinated efforts across data management, drug discovery, and clinical trials are turning potential into impact. Some are early-career researchers shaping their journeys, while others are leading international consortia advancing treatments towards patients.  

COMBINE and GNA NOW project member, Leonie von Berlin, Data Scientist at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) in Hamburg, Germany, represents the next generation of researchers driving change. Her work is focused on FAIRifying and harmonising data. “By making research outputs more sustainable and accessible to the wider scientific community,” she says, “we enhance their value and contribute to a more effective global response to antimicrobial resistance.” Her story is part of our early-career researchers interview series, which also includes interviews with scientists from GNA NOW and PrIMAVeRa, highlighting how the AMR Accelerator nurtures the next generation of AMR researchers. 

Moving from data management to drug development, the interview with Project Coordinator of the RespiriTB and RespiriNTM, Meindert Lamers, offers his insight into the AMR Research from his positions as the co-director of the Netherlands Center for Electron Nanoscopy (NeCEN) and the head of the Section Electron Microscopy at the Leiden University Medical Center (LUMC), the Netherlands. He emphasises the value of their hybrid academic-industry approach, showing how collaboration, shared expertise and clear goals guide early-stage compounds toward clinical testing. This interview provides a rare view of the strategic decisions and teamwork behind drug development. 

Continuing the insight into collaborative teamwork, the UNITE4TB Expert Interview Series provides a snapshot into what it takes to innovate tuberculosis treatment on four continents. Featuring 11 conversations with leading voices from across the consortium, the series explores the journey and vision of UNITE4TB, insights into clinical trials, diagnostics, & drug development, and the vital role of community engagement, public–private collaboration, and scientific innovation.

Other AMR Accelerator projects are contributing in equally significant ways, such as the ERA4TB interview series celebrating women in TB research. Ten brilliant ERA4TB researchers shared how tuberculosis disproportionately affects women and why women need to be involved in drug development research. As Anna Upton, Senior Vice President of Infectious Diseases at Evotec, says, “Women are a large part of the population, and we are affected by TB, so the female patient voice also needs to be represented. We cannot afford to not have women involved!”

Together with this compilation of interviews, we aim to bring the human side of research to the forefront. Across all nine AMR Accelerator projects, researchers are driving progress, innovation and bold action against AMR and TB. With every insight, every journey and every lesson, we celebrate the AMR Accelerator researchers, as they lead science today and work to protect our present and secure our future.